Physician profile
Peter A Liloia
NPI 1962601872
$4,510.40
in general payments reported to CMS, 2019-2025
40 companies · $1,985 in 2025
The $1,985 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2023: $440 · 2024: $1,774 · 2025: $1,985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,198.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $603.85 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $417.31 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $339.76 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $285.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $246.45 | 2019-2025 | |
| Abbvie INC. | $226.48 | 2023-2025 | |
| Lilly USA, LLC | $212.75 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $200.23 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $153.49 | 2024-2025 | |
| Astellas Pharma US INC | $151.72 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $140.07 | 2023-2025 | |
| Glaxosmithkline, LLC. | $124.36 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exeltis, USA INC. | $121.77 | 2024 | Slynd |
| Corcept Therapeutics | $121.37 | 2023-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.99 | 2019-2025 | Jardiance, Synjardy |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $113.38 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $96.93 | 2023-2025 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $87.90 | 2024-2025 | Aplenzin, Wellbutrin |
| Tolmar, INC. | $77.65 | 2025 | Jatenzo |
| Medtronic Minimed, INC. | $73.44 | 2019 | |
| Medtronic, INC. | $69.66 | 2023-2025 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $65.57 | 2024-2025 | Strensiq |
| Esperion Therapeutics, INC. | $62.32 | 2023-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $50.17 | 2019-2025 | Capvaxive, Gardasil 9, Lagevrio |
| Radius Health, INC. | $34.58 | 2025 | Tymlos |
| Mannkind Corporation | $34.08 | 2024-2025 | |
| Antares Pharma, INC. | $33.67 | 2025 | Xyosted |
| Paratek Pharmaceuticals, INC. | $32.66 | 2024 | Nuzyra |
| Ascendis Pharma Endocrinology INC | $32.24 | 2023-2025 | Yorvipath |
| Kowa Pharmaceuticals America, INC. | $21.15 | 2023 | Livalo |
| Tandem Diabetes Care, INC. | $18.63 | 2019 | |
| Insulet Corporation | $18.35 | 2023 | Omnipod |
| Kyowa Kirin, INC. | $17.62 | 2025 | |
| Ibsa Pharma INC. | $16.66 | 2024 | Licart, Tirosint |
| Halozyme INC | $16.59 | 2023 | |
| Currax Pharmaceuticals LLC | $16.06 | 2024 | Contrave |
| Genentech USA, INC. | $15.00 | 2019 | |
| Leo Pharma INC. | $14.99 | 2025 | Spevigo |
| Takeda Pharmaceuticals U.S.A., INC. | $12.82 | 2019 | |
| Lifescan, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Liloia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.